The secretion of prolactin (PRL) from pituitary lactotrophs of the rat is predominantly under inhibitory control exerted by dopamine (DA) of hypothalamic origin (1). Other PRL-inhibiting substances of hypothalamic origin include somatostatin and endothelin (ET) (2). The latter is the focus of a recent article from the Stojilkovic lab (3) and of this report. In addition to the PRL-inhibiting substances, a host of candidate PRL-releasing hormones, also of hypothalamic origin, exist (2). These include thyrotropin-releasing hormone (TRH), vasoactive intestinal polypeptide, angiotensin II, oxytocin (OT), and even DA itself (2). Each has well-described receptors on the lactotroph membrane and, in most cases, has well-defined postreceptor transduction cascades that regulate PRL secretion. These include the activation of excitatory or inhibitory guanosine triphosphate (GTP)-binding proteins (G proteins) (G s , G q , and G i/o ), which activate or inhibit adenylyl cyclase with downstream effects on adenosine 3′,5′-monophosphate (cAMP) formation or which activate phospholipase C (PLC). Although the nature of these pathways differs, they share one final common denominator: They each regulate PRL secretion by affecting the intracellular levels of calcium, the key ion evoking PRL exocytosis.The ETs are a family of vasoconstrictor peptides that were found in (4) and later purified from tissue culture media of vascular endothelial cells (5). Three different ET isopeptides encoded by three separate genes were identified and designated ET-1, -2, and -3 (6). Similarly, three types of ET receptors have been identified and cloned (7-9). In pituitary cells, endothelins operate through ET A receptors, which have greater affinity for ET-1 and ET-2 than for ET-3 (10). Early evidence suggested that the ETs may affect pituitary hormone secretion. Indeed, their mRNAs are found in the pituitary gland and in hypothalamic magnocellular nuclei (11,12). Moreover, ETs and their receptors are found in the anterior lobe of the pituitary gland (13), and ET-like immunoreactivity is found in lactotrophs, gonadotrophs, and somatotrophs (14). This suggests that the ETs may be autocrine regulators of pituitary hormone secretion (15).Other lines of evidence indicate that the ETs play a role in the secretion of hormones from the anterior pituitary gland. It has been reported that ETs acting at ET A receptors (10) diminish PRL secretion while enhancing luteinizing hormone, follicle-stimulating hormone, and thyroid-stimulating hormone secretion in vitro (16)(17)(18). In the presence of DA, the PRL secretory response to ET-1 is biphasic, consisting of an initial rapid high-amplitude stimulatory phase followed by a sustained modest elevation as long as ET-1 is present (19). In the absence of DA, the initial ET-mediated stimulatory response is followed by a sustained inhibition of PRL secretion, which lasts for tens of minutes after the removal of the ET-1 (19). The effect of ET-1 in lactotrophs is partially mediated by the activation of large-conductance Ca ...